Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus

Journal of Medical Virology

Volumn 87, Issue 1, 2015, Pages 39-44

  Lei, Han ^a   Peng, Xiaojue ^a   Shu, Handing ^a   Zhao, Daxian ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

H5N1 virus challenge; Intranasal immunization; L. lactis+LTB

Indexed keywords

AVIAN INFLUENZA VACCINE; HEAT LABILE TOXIN B SUBUNIT; HEMAGGLUTININ; IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL TOXIN; DRUG CARRIER; ENTEROTOXIN; ESCHERICHIA COLI PROTEIN; HEAT-LABILE ENTEROTOXIN, E COLI; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AVIAN INFLUENZA; CHICKEN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LACTOCOCCUS LACTIS; NONHUMAN; PANDEMIC INFLUENZA; ANIMAL; BLOOD; BODY WEIGHT; GENE VECTOR; GENETICS; IMMUNOLOGY; INFLUENZA IN BIRDS; INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; PATHOLOGY; PROCEDURES; SURVIVAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACTERIAL TOXINS; BODY WEIGHT; CHICKENS; DRUG CARRIERS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; LACTOCOCCUS LACTIS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84909594333     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23983     Document Type: Article

References (15)

1. Bahey-El-Din M. 2012. Lactococcus lactis-based vaccines from laboratory bench to human use: An overview. Vaccine 30:685-690.
2. Bermúdez-Humarán LG, Kharrat P, Chatel JM, Langella P. 2011. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 10:S4.
3. Germann TC, Kadau K, Longini IM Jr, Macken CA. 2006. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 103:5935-5940.
4. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, Chen LM, Donis RO, Compans RW. 2009. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 4:e4667.
5. Lei H, Xu Y, Chen J, Wei X, Lam DM. 2010. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407:319-324.
6. Li Z, Mooney AJ, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B. 2013. Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge. J Virol 87:354-362.
7. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G. 2001. Mucosal vaccines: Non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
8. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J. 2008. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 380:412-420.
9. Rappuoli R, Dormitzer PR. 2012. Influenza: Options to improve pandemic preparation. Science 336:1531-1533.
10. Saluja V, Amorij JP, vanRoosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW. 2010. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J 12:109-116.
11. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM. 2011. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci USA 108:757-761.
12. Wells JM, Mercenier A. 2008. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6:349-362.
13. Yuki Y, Kiyono H. 2003. New generation of mucosal adjuvant for the induction of protective immunity. Rev Med Virol 13:293-310.
14. Zhang J. 2012. Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses 4:2711-2735.
15. Zhou F, Wang G, Buchy P, Cai Z, Chen H, Chen Z, Cheng G, Wan XF, Deubel V, Zhou P. 2012. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J Virol 86:6970-6978.